Mucoactive drugs for asthma and COPD: any place in therapy?

Bibliography

• MEDICAL RESEARCH COUNCIL: Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet (1965) i:775–779.
   Google Scholar
• OPENSHAW PJ, TURNER-WARWICK M: Observations on sputum production in patients with variable airflow obstruction; implications for the diagnosis of asthma and chronic bronchitis. Rapt!: Med. (1989) 83:25–31.
   Web of Science ®Google Scholar
• AIKAWA T, SHIMURA S, SASAKI H, TAKISHIMA T, YAEGASHI H, TAKAHASHI T: Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am. Rev Emir: Dir. (1989) 140:477–482.
   PubMed Web of Science ®Google Scholar
• AIKAWA T, SHIMURA S, SASAKI H, EBINA M, TAKISHIMA T: Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest (1992) 101:916–921.
   PubMed Web of Science ®Google Scholar
• REID L: Pathology of chronic bronchitis. Lancet (1954) 1:275–278.
   Web of Science ®Google Scholar
• ORDONEZ CL, KHASHAYARR, WONGHH et al.: Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am. J. Emir: Grit. Care Med. (2001) 163:517–523.
   PubMed Web of Science ®Google Scholar
• JEFFERY PK: Differences and similaritiesbetween chronic obstructive pulmonary disease and asthma. Clin. Exp. Allergy (1999) 29 (Suppl. 2):14–26.
   Google Scholar
• •Comprehensive review of the pathological, histopathological and pathophysiological differences between asthma and COPD.
   Google Scholar
• WIDDICOMBE JH, WIDDICOMBE JG: Regulation of human airway surface liquid. Respir. Physial (1995) 99:3–12.
   PubMedGoogle Scholar
• ROGERS DF: Airway goblet cells: responsive and adaptable front-line defenders. Eur. Respir. J. (1994) 7:1690–1706.
   PubMed Web of Science ®Google Scholar
• FINKBEINER WE: Physiology and pathology of tracheobronchial glands. Respir. Physial (1997) 118:77–83.
   Google Scholar
• JEFFERY PK, LID: Airway mucosa: secretory cells, mucus and mucin genes. Eur. Respir J. (1997) 10:1655–1662.
   PubMed Web of Science ®Google Scholar
• DAVIES JR, CARLSTEDT I: Respiratory tract mucins. In: Cilia and mucus: from development to respiratory defense. Salthe M (Ed.) Marcel Dekker, Inc., New York, USA (2001): 167–178.
   Google Scholar
• •Up-to-date review of the biochemistry of the large gel-forming mucins.
   Google Scholar
• ROSE MC, GENDLER SJ: Airway mucin genes and gene products. In: Airway mucus: basic mechanisms, and clinical perspectives Rogers DF and Lethem MI (Eds.) Basel, Birkhäuser Verlag (1997): 41–66.
   Google Scholar
• LAPENSEE L, PAQUETTE Y, BLEAU G: Allelic polymorphism and chromosomal localization of the human oviductin gene (MUC9). Feral. Sten]. (1997) 68:702–708.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SJ, MCGUCKIN MA, GOTLEY DC, EYRE HJ, SUTHERLAND GR, ANTALIS TM: Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res. (1999) 59:4083–4089.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SJ, WRESCHNERDH, TRAN M, EYRE HJ, SUTHERLAND GR, MCGUCKIN MA: Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. 1. Biol. Chem. (2001) 276:18327–18336.
   Google Scholar
• YIN BW, LLOYD KO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. Biol. Chem. (2001) 276:27371–27375.
   Web of Science ®Google Scholar
• DAVIES JR, SVITACHEVA N, LANNEFORS L, KORNFALT R, CARLSTEDT I: Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions. Biochem. J. (1999) 344 (Pt 2):321–330.
   PubMed Web of Science ®Google Scholar
• HOVENBERG HW, DAVIES JR, CARLSTEDT I: Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem. 1 (1996) 318:319–324.
   PubMed Web of Science ®Google Scholar
• WICKSTROM C, DAVIES JR, ERIKSEN GV, VEERMAN EC, CARLSTEDT I: MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem. J. (1998) 334:685–693.
   PubMed Web of Science ®Google Scholar
• HOVENBERG HW, DAVIES JR, HERRMANN A, LINDEN CJ, CARLSTEDT I: MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Clycocorg. J. (1996) 13:839–847.
   Google Scholar
• THORNTON DJ, DAVIES JR, KRAAYENBRINK M, RICHARDSON PS, SHEEHAN JK, CARLSTEDT I: Mucus glycoproteins from 'normal human tracheobronchial secretion. Biochem. (1990) 265:179–186.
   Google Scholar
• THORNTON DJ, CARLSTEDT I, HOWARD M, DEVINE PL, PRICE MR, SHEEHAN JK: Respiratory mucins: identification of core proteins and glycoforms. Biochem. 1 (1996) 316:967-975.
   Google Scholar
• DUNNILL MS: The pathology of asthma with special reference to changes in the bronchial mucosa. 1. Clin. Pathal (1960) 13:27–33.
   PubMed Web of Science ®Google Scholar
• •The definitive description of asthma pathology.
   Google Scholar
• HOUSTON JC, DE NAVASQUEZ S, TROUNCE JR: A clinical and pathological study of fatal cases of status asthmaticus. Thorax (1953) 8:207–213.
   PubMed Web of Science ®Google Scholar
• SAETTA M, DI STEFANO A, ROSINA C, THIENE G, FABBRI LM: Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am. Rev. Respir. Dis. (1991) 143:138–143.
   PubMed Web of Science ®Google Scholar
• KEAL EE, REID L: Pathological alterations in mucus in asthma within and without the cell. In: New directions in asthma. Stein M (Ed.) Park Ridge, American College of Chest Physicians, USA (1975): 223–239.
   Google Scholar
• BHASKAR KR, O'SULLIVAN DD, COLES SJ, KOZAKEWICH H, VAWTER GP, REID LM: Characterization of airway mucus from a fatal case of status asthmaticus. Pediatr. Pulmorral (1988) 5:176–182.
   PubMed Web of Science ®Google Scholar
• FELDH OFF PA, BHAVANANDAN DAVIDSON EA: Purification, properties, and analysis of human asthmatic bronchial mucin. Biochemistry (1979) 18:2430–2436.
   PubMed Web of Science ®Google Scholar
• SHEEHAN JK, RICHARDSON PS, FUNG DC, HOWARD M, THORNTON DJ: Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am. I Respir Cell Mal Biol. (1995) 13:748–756.
   PubMed Web of Science ®Google Scholar
• •Definitive description of the biochemical characteristics of a mucus plug from an asthmatic patient.
   Google Scholar
• DUNNILL MS, MASSARELLA GR, ANDERSON JA: A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax (1969) 24:176–179.
   PubMed Web of Science ®Google Scholar
• DUNNILL MS: The morphology of the airways in bronchial asthma. In: New irections in Asthma Stein M (Ed.) Park Ridge, American College of Physicians (1975):213–221.
   Google Scholar
• SANERKIN NG, EVANS DMD: The sputum in bronchial asthma: pathognomic patterns. J Pathal Bacterial (1965) 89:535–541.
   PubMed Web of Science ®Google Scholar
• LOPEZ-VIDRIERO MT, REID L: Bronchial mucus in health and disease. Br. Med. Bull. (1978) 34:63–74.
   PubMed Web of Science ®Google Scholar
• FAHY JV, STEIGER DJ, LIU J, BASBAUMCB, FINKBEINER WE, BOUSHEY HA: Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. Am. Rev Respir. Dis. (1993) 147:1132–1137.
   PubMed Web of Science ®Google Scholar
• LOPEZ-VIDRIERO MT, REID L: Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases. Am. Rev Respir D (1978) 117: 465–477.
   PubMed Web of Science ®Google Scholar
• FAHY JV, LIU J, WONG H, BOUSHEYHA: Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev Respir. Dis. (1993) 147:1126–1131.
   PubMed Web of Science ®Google Scholar
• CHARMAN J, REID L: Sputum viscosity inchronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology (1972) 9:185–199.
   PubMedGoogle Scholar
• SHIMURA S, SASAKI T, SASAKI H, TAKISHIMA T, UMEYA K: Viscoelastic properties of bronchorrhoea sputum in bronchial asthmatics. Biorheology (1988) 25:173–179.
   PubMed Web of Science ®Google Scholar
• SNIDER GL, EALING LJ, RENNARD SI: Chronic bronchitis and emphysema. In: Textbook of respiratory medicine. Murray JF and Nadel JA (Eds.) W.B. Saunders, Philadelphia, USA (1999): 1331–1397.
   Google Scholar
• STEIGER D, FAHY J, BOUSHEY H, FINKBEINER WE, BASBAUM C. Use of mucin antibodies and cDNA probes to quantify hypersecretion in vivo in human airways. Am. j. Respir: Cell Mal Biol. (1994) 10:538–545.
   Google Scholar
• ROGERS DF: Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch. Chest Dis. (2000) 55:324–332.
   PubMedGoogle Scholar
• REID L: Measurement of the bronchial mucous gland layer: a diagnostis yardstick in chronic bronchitis. Thorax (1960) 15:132–141.
   PubMedGoogle Scholar
• RESTREPO G, HEARD BE: The size of the bronchial glands in chronic bronchitis. I Pathol. Bacterial (1963) 85:305–310.
   PubMedGoogle Scholar
• GLYNN AA, MICHAELS L: Bronchial biopsy in chronic bronchitis and asthma. Thorax (1960) 15:142–153.
   Google Scholar
• •Makes the novel assertion that the increased ratio of mucous to serous acini in the submucosal glands is the cardinal feature of the pathology of chronic bronchitis.
   Google Scholar
• SAETTA M, TURATO G, BARALDO S et al.: Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Respir: Grit. Care Med. (2000) (2000) 161:1016–1021.
   Google Scholar
• MULLEN JB, WRIGHT JL, WIGGS BR,PARE PD, HOGG JC: Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax (1987) 42:843–848.
   PubMed Web of Science ®Google Scholar
• WIDDICOMBE JG: A critical look at mucus markers. In: Inflammatory indices of chronic bronchitis. Persson CGA, Brattsand RLLA (Eds.) Birkhauser Verlag, Basel, Switzerland (1990): 269–279.
   Google Scholar
• HAYES JA: Distribution of bronchial gland measurement in a Jamaican population. Thorax (1960) 24:619–622.
   Web of Science ®Google Scholar
• THURLBECK WM, ANGUS GE: A distribution curve for chronic bronchitis. Thorax (1964) 19:436–442.
   PubMedGoogle Scholar
• THURLBECK WM, ANGUS CW, PARE JAP: Mucous gland hypertrophy in chronic bronchitis, and its occurence in smokers. Brit. Dis. Chest (1963) 57:73–78.
   PubMedGoogle Scholar
• LIU YC, KHAWAJA AM, ROGERS DF: Pathophysiogy of airway mucus secretion in asthma. In: Asthma. Basic mechanisms, and clinical management Barnes PJ, Rodger IW, and Thomson NC (Eds.) London, Academic Press, London, England (1997): 205–227.
   Google Scholar
• ROGERS DF, EVANS TW: Plasma exudation and oedema in asthma. Br Med. Bull. (1992) 48:120–134.
   PubMed Web of Science ®Google Scholar
• SHEEHAN JK, HOWARD M, RICHARDSON PS, LONGWILL T, THORNTON DJ: Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug. Biochem. 1 (1999) 338:507–513.
   PubMed Web of Science ®Google Scholar
• SHIMURA S, AND OH Y, HARAGUCHI M, SHIRATO K: Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur. Respir. J. (1996) 9:1395–1401.
   PubMed Web of Science ®Google Scholar
• •Demonstration that in asthma goblet cells do not fully release their secreted mucin, possibly contributing to plug formation in the airways.
   Google Scholar
• O'RIORDAN TG, ZWANG J, SMALDONE GC: Mucociliary clearance in adult asthma. Ain. Rev Respir: Dis. (1992) 146:598–603.
   PubMed Web of Science ®Google Scholar
• MESSINA MS, O'RIORDAN TG, SMALDONE GC: Changes in mucociliary clearance during acute exacerbations of asthma. Ain. Rev Respir. Dis. (1991) 143:993–997.
   PubMed Web of Science ®Google Scholar
• RUSSI EW, ABRAHAM WM, CHAPMAN GA, STEVENSON JS, CODIAS E, WANNER A: Effects of leukotriene D4 on mucociliary and respiratory function in allergic and nonallergic sheep. I Appl. Physial. (1985) 59:1416–1422.
   PubMed Web of Science ®Google Scholar
• FRIGAS E, LOEGERING DA, GLEICH GJ: Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab. Invest. (1980) 42:35–43.
   PubMed Web of Science ®Google Scholar
• MOTOJIMA S, FRIGAS E, LOEGERING DA, GLEICH GJ: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am. Rev Respir Dis. (1989) 139:801–805.
   PubMed Web of Science ®Google Scholar
• AYERS MM, JEFFERY PK: Proliferation and differentiation in mammalian airway epithelium. Eur. Respir: 1 (1988) 1:58-80.
   Google Scholar
• FERRER A, ROCA J, WAGNER PD, LOPEZ FA, RODRIGUEZ-ROISIN R: Airway obstruction and ventilation-perfusion relationships in acute severe asthma. Am. Rev. Respir: Dis. (1993) 147:579–584.
   PubMed Web of Science ®Google Scholar
• WAGNER PD, HEDENSTIERNA G, RODRIGUEZ-ROISIN R: Gas exchange, expiratory flow obstruction and the clinical spectrum of asthma. Eur. Respir 1 (1996) 9:1278–1282.
   Google Scholar
• WIGGS B, MORENO R, JAMES A, HOGG JC, PARE PD: A model of the mechanics of airway narrowing in asthma. In: Asthma: its pathology and treatment. Kanner MA, Barnes PJ, Persson CGA (Eds.) Marcel Dekker, New York, USA (1996): 73–101.
   Google Scholar
• HARGREAVE FE, RYAN G, THOMSON NC, O'BYRNE PM, LATIMER K, JUNIPER EF: Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. Eur. I Respir: Dis. (1982) 121 (Suppl.):79–88.
   Google Scholar
• SUZUKI T, INOUE H, LIN J-T, TAKISHIMA T: Intraluminal space occupying substance induces airway hyperresponsiveness. Am. Rev Respir: Dis. (1992) 145 (Suppl.):A50.
   Google Scholar
• YAGER D, SHORES, DRAZEN JM: Airway luminal liquid. Sources and role as an amplifier of bronchoconstriction. Am. Rev Respir: Dis. (1991) 143:S52–S54.
   PubMedGoogle Scholar
• KING M, KELLY S, COSIO M: Alteration of airway reactivity by mucus. Respir Physial. (1985) 62:47–59.
   PubMedGoogle Scholar
• KIM CS, ELDRIDGE MA: Aerosol deposition in the airway model with excessive mucus secretions. I Appl. Physial. (1985) 59:1766–1772.
   PubMed Web of Science ®Google Scholar
• KIM CS, ELDRIDGE MA, WANNER A:Airway responsiveness to inhaled and intravenous carbachol in sheep: effect of airway mucus. I Appl. Physial. (1988) 65:2744–2751.
   PubMed Web of Science ®Google Scholar
• KIM CS, ABRAHAM WM, GARCIA L, SACKNER MA: Enhanced aerosol deposition in the lung with mild airways obstruction. Ain. Rev Respir. Dis. (1989) 139:422–426.
   PubMed Web of Science ®Google Scholar
• HOGG JC, MACKLEM PT, THURLBECK WM: Site and nature of airway obstruction in chronic obstructive lung disease. N Engl. I Med (1968) 278:1355–1360.
   PubMed Web of Science ®Google Scholar
• •Demonstration that the small airways are the principle site of airway obstruction in COPD.
   Google Scholar
• FLETCHER C, PETO R: The natural history of chronic airflow obstruction. Br. Med. J. (1977) 1:1645–1648.
   PubMed Web of Science ®Google Scholar
• •Definitive epidemiological study showing that cigarette smoking is the cause of irreversible obstructive changes in the lungs of susceptible people.
   Google Scholar
• KAUFFMANN F, DROUET D, LELLOUCH J, BRILLE D: Twelve years spirometric changes among Paris area workers. Intl Epidemial. (1979) 8:201–212.
   PubMed Web of Science ®Google Scholar
• PETO R, SPEIZER FE, COCHRANE AL et al.: The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am. Rev Respir. Dis. (1983) 128:491–500.
   Google Scholar
• EBI-KRYSTON KL: Respiratory symptomsand pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. I Clirr. Epidemiol (1988) 41:251–260.
   PubMed Web of Science ®Google Scholar
• HIGGINS MW, KELLER JB, BECKER Metal.: An index of risk for obstructive airways disease. Am. Rev Respir: Dis. (1982) 125:144–151.
   PubMed Web of Science ®Google Scholar
• ANNESI I, KAUFFMANN F: Is respiratorymucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1,061 working men. Am. Rev Respir: Dis. (1986) 134:688–693.
   Google Scholar
• VESTBO J, PRESCOTT E, LANGE P: Association of chronic mucus hypersecretion with FEVi decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. I Respir Grit. Care Med. (1996) 153:1530–1535.
   PubMed Web of Science ®Google Scholar
• LANGE E NYBOE J, APPLEYARD M, JENSEN G, SCHNOHR P: Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax (1990) 45:579–585.
   PubMed Web of Science ®Google Scholar
• PRESCOTT E, LANGE E VESTBO J: Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir: J. (1995) 8:1333–1338.
   PubMed Web of Science ®Google Scholar
• ••Important epidemiological study showingthe relationship between chest infection and 'phlegm' production in patients who die of COPD.
   Google Scholar
• SPEIZER FE, FAY ME, DOCKERY DW, FERRIS BG, Jr: Chronic obstructive pulmonary disease mortality in six U.S. cities. Am. Rev. Respir Dis. (1989) 140:S49–S55.
   PubMedGoogle Scholar
• SHERMAN CB, XU X, SPEIZER FE, FERRIS BG, Jr., WEISS ST, DOCKERY DW: Longitudinal lung function decline in subjects with respiratory symptoms. Am. Rev Respir: Dis. (1992) 146:855–859.
   Google Scholar
• Indice Actualizado de Especialidades Medicinales. AP Americana de Publicaciones S.A., 1998.
   Google Scholar
• Australian Medicines Handbook. Adelaide, Australian Medicines Handbook Pty Ltd, 1998.
   Google Scholar
• Belgisch Centrum voor FarmakoterapeutischeInformatie. Cecommentarieerd Ceneesmiddelen-Repertmium. Belgium, Centre Belge d'Information Pharmacotherapeutique, 1998.
   Google Scholar
• DicionMio de Especialidades FarmarCutkas. Rio de Janeiro, Publicagies Cientificas, 1997.
   Google Scholar
• Lääkevalmisteet Pharmaca Fennica. Rauma, Lääketietokeskus Oy, 1998.
   Google Scholar
• Le Dictionaire. Paris, Editions du Vidal, 1999.
   Google Scholar
• Die Rote Liste. Berlin, Bundesverband Pharmazeutische Industrie, 1999. 108.
   Google Scholar
• Ireland Monthly Index of Medical Specialities (MIMS). Dublin, Medical Publications (Ireland) Ltd, 2001. 109.
   Google Scholar
• Informatore Farmaceutico. Milan, OEMF International, 1998.
   Google Scholar
• Today's Therapy Tokyo, Igaku Shoin Ltd, 1999.
   Google Scholar
• Farmaco-therapeutisch Kompas. Rotterdam,110. Erasmus Publishing, 1998.
   Google Scholar
• New Ethicals. Aukland, Adis International, 1999.
   Google Scholar
• Medicinal Reference Book Russia VIDAL.111. Moscow, Astra Pharma Service, 1997.
   Google Scholar
• South African Medicines Formulary Pinelands, Medical Association of SouthAfrica, Publications Department, 1997.
   Google Scholar
• FASS Stockholm, LINFO 112. Läkemedelsinformation, 1998.
   Google Scholar
• Arzneimittelkompendium der Schweiz. Basel, Documed AG, 1999.
   Google Scholar
• Handbook of Common Drugs, Version 1999. Taiwan, Shin Xing Ltd., 1999.
   Google Scholar
• BRITISH MEDICAL ASSOCIATION AND THE ROYAL PHARMACEUTICAL •• SOCIETY OF GREAT BRITAIN. British National Formulary. London, British Medical Association and the Royal Pharmaceutical Society of Great Britain,113.2001.
   Google Scholar
• US Physicians Desk Reference. Montvale, Medical Economics Company, Inc., 1999.
   Google Scholar
• BRITISH THORACIC SOCIETY. BTS guidelines for the management of chronic obstructive pulmonarty disease. Thorax 52 (Suppl. 5):S1–S281997.
   Google Scholar
• SIAFAKAS NM, VERMEIREP, PRIDE NB et al.: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. 1 (1995) 8:1398-1420.
   Google Scholar
• CANADIAN THORACIC SOCIETY WORKSHOP GROUP: Guidelines for the assessment and management of chronic obstructive pulmonary disease. Can. Med. Assoc. (1992) 147:420–428.
   PubMed Web of Science ®Google Scholar
• AMERICAN THORACIC SOCIETY: Standars for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir Grit. Care Med. (1995) 152 (Suppl.):S77–S120.
   Google Scholar
• JENKINS C, MITCHELL C, IRVING L, FRITH P, YOUNG I: Guidelines for the management of chronic obstructive disease. Mod. Med. Australia (1995) 38:132–146.
   Google Scholar
• BRITISH THORACIC SOCIETY: The British guidelines on asthma management. Thorax (1997) 52 (Suppl. 1):S1–521.
   Google Scholar
• AMERICAN THORACIC SOCIETY: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. Rev. Respir. Dis. (1987) 136:225–244.
   PubMed Web of Science ®Google Scholar
• HOUTMEYERS E, GOSSELINK R, GAYAN-RAMIREZ G, and DECRAMER M: Effects of drugs on mucus clearance. Eur. Respir J. (1999) 14:452–467.
   PubMed Web of Science ®Google Scholar
• BRIDGEMAN MM, MARSDEN M, MACNEE W, FLENLEY DC, RYLE AP: Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax (1991) 46:39–42.
   PubMed Web of Science ®Google Scholar
• GRANDJEAN EM, BERTHET P, RUFFMANN R, LEUENBERGER P: Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. (2000) 22:209–221.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis of published reports showingthat long-term treatment with N-acetylcysteine reduces exacerbations of COPD. POOLE PJ, BLACK PN: Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ (2001) 322:1271-1274. Meta-analysis of published reports showing that long-term treatment with a range of mucolytic drugs reduces exacerbations of COPD.
   Google Scholar
• EKBERG-JANSSON A, LARSON M, MACNEE W et al.: N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur. Respir J. (1999) 13:829–834.
   PubMed Web of Science ®Google Scholar
• RIISE GC, LARSSON S, LARSSON P, JEANSSON S, ANDERSSON BA: The intrabronchial microbial flora in chronic bronchitis patients: a target for N-113. acetylcysteine therapy? Eur. Respit: 1 (1994) 7:94-101.
   Google Scholar
• RUSE GC, QVARFORDT I, LARSSON S, ELIASSON V, ANDERSSON BA: Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration (2000) 67:552–558.
   PubMed Web of Science ®Google Scholar
• WANG Y, GRIFFITHS WJ, CURSTEDT T, JOHANSSON J: Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a C-terminal 18-residue fragment thereof. FELS Lett. (1999) 460:257–262.
   PubMed Web of Science ®Google Scholar
• NOWAK D, ANTCZAK A, KROL M, BIALASIEWICZ E PIETRAS T: Antioxidant properties of Ambroxol. Free Radic. Biol. Med. (1994) 16:517–522.
   PubMed Web of Science ®Google Scholar
• BRAGA PC: Mucus pharmacology. Respiration (1991) 58 (Suppl. 1):47–51.
   Google Scholar
• YUTA A, BARANIUK JN: Therapeutic approaches to airway hypersecretion. In: Airway mucus: basic mechanisms and clinical perspectives. Rogers DF, Lethem MI (Eds.) Birkhauser Verlag, Basel, Switzerland (1997): 365–383.
   Google Scholar
• THORNTON DJ, DAVIES JR, CARLSTEDT I, SHEEHAN JK: Structure and biochemistry of human respiratory mucins. In: Airway mucus: basic mechanisms and clinical perspectives. Rogers DF, Lethem MI (Eds.) Birkhauser Verlag, Basel, Switzerland (1997): 19–39.
   Google Scholar
• ZIMENT I: Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration (1986) 50 (Suppl. 1):26–30.
   Google Scholar
• SHEFFNER AL, MEDLER EM, JACOBS LW, SARETT HP: The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am. Rev Respit: Dis. (1964) 90:721–729.
   PubMed Web of Science ®Google Scholar
• RHEE CS, MAJIMA Y, CHO JS, ARIMA S, MIN YG, SAKAKURA Y: Effects of mucokinetic drugs on rheological properties of reconstituted human nasal mucus. Arch. Otolaryngol Head Neck Surg. (1999) 125:101–105.
   PubMed Web of Science ®Google Scholar
• MARTIN R, LITT M, MARRIOTT C: The effect of mucolytic agents on the rheologic and transport properties of canine tracheal mucus. Am. Rev Respir. Dis. (1980) 121:495–500.
   PubMed Web of Science ®Google Scholar
• ROGERS DF, JEFFERY PK: Inhibition by oral N-acetylcysteine of cigarette smoke-induced 'bronchitis' in the rat. Exp. Lung Res. (1986) 10:267-283. Demonstration that a 'mucolytic' drug can inhibit chronic induction of goblet cell hyperplasia in an experimental model of COPD.
   Google Scholar
• ROGERS DF, TURNER NC, MARRIOTT C, JEFFERY PK: Oral N-acetylcysteine or 5-carboxymethylcysteine inhibit cigarette smoke-induced hypersecretion of mucus in rat larynx and trachea in situ. Eur. Respit: I (1989) 2:955–960.
   Google Scholar
• ROGERS DF, GODFREY RW, MAJUMDAR S, JEFFERY PK: Oral N-acetylcysteine speeds reversal of cigarette smoke-induced mucous cell hyperplasia in the rat. Exp. Lung Res. (1988) 14:19–35.
   PubMed Web of Science ®Google Scholar
• BORGSTROM L, KAGEDAL B, PAULSEN 0: Pharmacokinetics of N-acetylcysteine in man. Eur. I Clin Pharmacol (1986) 31:217–222.
   PubMed Web of Science ®Google Scholar
• BONANOMI L, GAZZANIGA A: Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur. Respir. Dis. (1980) 111 (Suppl.):45–51.
   Google Scholar
• COTGREAVE IA, EKLUND A, LARSSON K, MOLDEUS PW: No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur. I Respir. Dis. (1987) 70:73–77.
   PubMedGoogle Scholar
• TSAN ME DANIS EH, DEL VECCHIO PJ, ROSANO CL: Enhancement of intracellular glutathione protects endothelial cells against oxidant damage. Biochem. Biophys. Res. Commun. (1985) 127:270–276.
   PubMed Web of Science ®Google Scholar
• BRIDGEMAN MM, MARSDEN M, SELBY C, MORRISON D, MACNEE W: Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax (1994) 49:670–675.
   PubMed Web of Science ®Google Scholar
• DUEHOLM M, NIELSEN C, THORSHAUGE H et al.: N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir. Med. (1992) 86:89–92.
   PubMed Web of Science ®Google Scholar
• AYLWARD M, MADDOCK J, DEWLAND P: Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control. Eur. Respir. Dis. (1980) 111 (Suppl.):81–89.
   Google Scholar
• MULTICENTRE STUDY GROUP: Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur. I Respir. Dis. (1980) 61 (Suppl.):93–108.
   Google Scholar
• BOMAN G, BACKER U, LARSSON S, MELANDER B, WAHLANDER L: Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur. j Respit: Dis. (1983) 64:405–415.
   PubMedGoogle Scholar
• BRITISH THORACIC SOCIETY RESEARCH COMMITTEE: Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax (1985) 40:832–835.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN JB, GLENNOW C: Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur. Respir J. (1988) 1:351–355.
   PubMed Web of Science ®Google Scholar
• HANSEN NC, SKRIVER A, BRORSEN-RIIS L et al.: Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir. Med. (1994) 88:531–535.
   PubMed Web of Science ®Google Scholar
• MARRIOTT C, INGHAM S, COFFINER M, FOSSION J, MAES P: Determination of the mode of action of a novel mucolytic agent, nacystelyn. Eur. Respir. 1 (1993) 6 (Suppl.):438s.
   Google Scholar
• TOMKIEWICZ RP, APP EM, DE SANCTIS GT, etal.: A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulm. Pharmacol. (1995) 8:259–265.
   Google Scholar
• GILLISSEN A, JAWORSKA M, ORTH M et al.: Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir. Med. (1997) 91:159–168.
   PubMed Web of Science ®Google Scholar
• NAGY AM, VANDERBIST F, PARIJ N, MAES P, FONDU P, NEVE J: Effect of the mucoactive drug nacystelyn on the respiratory burst of human blood polymorphonuclear neutrophils. Pulm. Pharmacol. Ther. (1997) 10:287–292.
   PubMed Web of Science ®Google Scholar
• AYLWARD M, BATER PA, DAVIES DE et al.: Clinical therapeutic evaluation of methylcysteine hydrochloride in patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control. Cun: Med. Res. Opin (1978) 5:461–471.
   PubMed Web of Science ®Google Scholar
• TEKERES M, HORVATH A, BARDOSI L, KENYERES P: Clinical studies on the mucolytic effect of mesna. Cli rt. Ther. (1981) 4:56–60.
   PubMed Web of Science ®Google Scholar
• KONRAD OVA V, VAVROVA V, SULOVAJ: Comparison of the effect of three oralmucolytics on the ultrastructure of the tracheal epithelium in rabbits. Respiration (1985) 48:50–57.
   PubMed Web of Science ®Google Scholar
• BROWN DT: Carbocysteine. Drug Intell Phann (1988) 22:603–608.
   Google Scholar
• MAJIMA Y, HIRATA K, TAKEUCHI K, HATTORI M, SAKAKURA Y: Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respit: Dis. (1990) 141:79–83.
   PubMed Web of Science ®Google Scholar
• BRAGA PC, ALLEGRA L, BOSSI R et al.: Identification of subpopulations of bronchitic patients for suitable therapy by a dynamic rheological test. Int. I Clin. Pharmacol Res. (1989) 9:175–182.
   PubMed Web of Science ®Google Scholar
• HAVEZ R, DEGAND P, ROUSSEL P, RANDOUX A: Biochemical mode of action of cysteine by-products on the bronchial mucus. Poumon.Coeur (1970) 26:81–90.
   PubMedGoogle Scholar
• THOMSON ML, PAVIA D, JONES CJ, MCQUISTON TA: No demonstrable effect of 5-carboxymethylcysteine on clearance of secretions from the human lung. Thorax (1975) 30:669–673.
   PubMed Web of Science ®Google Scholar
• EDWARDS GF, STEEL AE, SCOTT JK, JORDAN JW: S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest (1976) 70:506–513.
   PubMed Web of Science ®Google Scholar
• PUCHELLE E, AUG F, POLU JM: Effect of the mucoregulator S-carboxy-methyl-cysteine in patients with chronic bronchitis. Eur. Pharmacol. (1978) 14:177–184.
   Web of Science ®Google Scholar
• BRAGA PC, SCAGLIONE F, SCARPAZZA G et al.: Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int. I Clin. Pharmacol Res. (1985) 5:331–340.
   PubMed Web of Science ®Google Scholar
• BRAGA PC, BOSSI R, ALLEGRA L: Evaluation of the elastic and viscous components of bronchial mucus before and after S-carboxymethylcysteine-Lys treatment. Int. J.Pharmacol Res. (1984) 4:121–127.
   PubMedGoogle Scholar
• BRAGA PC, BORSA M, DE ANGELIS Let al.: Pharmacokinetic behavior of 5-carboxymethylcysteine-Lys in patients with chronic bronchitis. Chia. Ther. (1982) 4:480–488.
   Google Scholar
• BRAGA PC, ALLEGRA L, RAMPOLDI C, ORNAGHI A, BEGHI G: Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration (1990) 57:353–358.
   PubMed Web of Science ®Google Scholar
• ALLEGRA L, CORDARO CI GRASSI C: Prevention of acute exacerbations of chronic bronchitis with carbocysteine lysine salt monohydrate: a multicentre, double-blind, placebo-controlled trial. Respiration (1996) 63:174–180.
   PubMed Web of Science ®Google Scholar
• DECHANT KL, NOBLE S: Erdosteine. Drugs (1996) 52:875–881.
   PubMed Web of Science ®Google Scholar
• MARCHIONI CF, MORETTI M, MURATORI M et al.: Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung (1990) 168:285–293.
   PubMed Web of Science ®Google Scholar
• OLIVIERI D, DEL DONNO M, CASALINI A, D'IPPOLITO R, FREGNAN GB: Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration (1991) 58:91–94.
   PubMed Web of Science ®Google Scholar
• RICEVUTI G, MAZZONE A, UCCELLI E, GAZZANI G, FREGNAN GB: Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax (1988) 43:585–590.
   PubMed Web of Science ®Google Scholar
• VAGLIASINDI M, FREGNAN GB: Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures. Int. j Chia. Pharmacol Ther. Toxicol (1989) 27:238–241.
   PubMedGoogle Scholar
• MARCHIONI CE POLU JM, TAYTARD A, HANARD T, NOSEDA G, MANCINI C: Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int.j Clin. Pharmacol. Ther. (1995) 33:612–618.
   PubMed Web of Science ®Google Scholar
• BRAGA PC, BOSSI R, ALLEGRA L: Rheological modifications of mucus in chronic bronchitic patients after treatment with stepronine-lysine salt. Drugs Exp. Res. (1987) 13:707–710.
   PubMed Web of Science ®Google Scholar
• YAMADA K, SATOH M, SHIMURA S, SASAKI T, TAKISHIMA T, SHIRATO K: An expectorant, stepronin, reduces airway secretion in vitro. Respiration (1994) 61:42–47.
   PubMed Web of Science ®Google Scholar
• DAVIS SS, COX A, MARRIOTT C, READMAN AS, BARRETT-BEE K: A new mucotropic agent--in vitro and in vivo evaluation of 2-alpha-thenoylthiopropionylglycine (bronchoplus). Eur. Respir: Dis. (1985) 67:94–102.
   Google Scholar
• ROMANO A, DI FONSO M, MORMILE F, QUARATINO D, GIUFFREDA F, VENUTI A: Accelerated cell-mediated broncho-obstructive reaction to inhaled stepronin: a case report. Allergy (1996) 51:269–271.
   PubMed Web of Science ®Google Scholar
• DISSE BG: The pharmacology of ambroxol: review and new results. Eur. I Respir: Dis. (1987) 153 (Suppl.):255–262.
   Google Scholar
• LUSUARDI M, CAPELLI A, SALMONA M, TACCONI MT, CERUTTI CG, DONNER CF: Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol Monaldi Arch. Chest Dis. (1995) 50:346–351.
   Google Scholar
• OLIVIERI D, MARSICO SA, DEL DONNO M: Improvement of mucociliary transport in smokers by mucolytics. Eur. Respit: Dis. (1985) 139 (Suppl.):142–145.
   Google Scholar
• WEISS T, DOROW E FELIX R: Effects of a beta adrenergic drug and a secretolytic agent on regional mucociliary clearance in patients with COLD. Chest (1981) 80:881–885.
   PubMed Web of Science ®Google Scholar
• ERICSSON CH, JUHASZ J, MOSSBERG B, PHILIPSON K, SVARTENGREN M, CAMNER P: Influence of ambroxol on tracheobronchial clearance in simple chronic bronchitis. Eur. Respit: Dis. (1987) 70:163–170.
   PubMedGoogle Scholar
• GERMOUTY J, JIROU-NAJOU JL: Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration (1987) 51 (Suppl. 1):37–41.
   Google Scholar
• ERICSSON CH, JUHASZ J, JONSSON E, MOSSBERG B: Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. Respiration (1987) 51 (Suppl. 1):33–36.
   Google Scholar
• GUYATT GH, TOWNSEND M, KAZIM F, NEWHOUSE MT: A controlled trial of ambroxol in chronic bronchitis. Chest (1987) 92:618–620.
   PubMed Web of Science ®Google Scholar
• OLIVIERI D, ZAVATTINI G, TOMASINI G et al.: Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration (1987) 51 (Suppl. 1):42–51.
   Google Scholar
• ANON: Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients. Respiration (1989) 55 (Suppl. 1):84–96.
   Google Scholar
• PAGANIN F, BOUVET 0, CHANEZ P et al: Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Biopharm. Drug Dispos. (1995) 16:393–401.
   PubMed Web of Science ®Google Scholar
• MARTIN GP, LOVEDAY BE, MARRIOTT C: The effect of bromhexine hydrochloride on the viscoelastic properties of mucus from the mini-pig. Eur. Respir. 1 (1990) 3:392–396.
   PubMed Web of Science ®Google Scholar
• YANAURA S, TAKEDA H, NISHIMURA T, MISAWA M: [Histological and histochemical changes of tracheal secretory cells following bromhexine treatment (author's trans1)]. Nippon Yakurigaku Zasshi (1981) 77:559–568.
   PubMed Web of Science ®Google Scholar
• VALENTI S, MARENCO G: Italian multicenter study on the treatment of chronic obstructive lung disease with bromhexine. A double-blind placebo-controlled trial. Respiration (1989) 56:11–15.
   Google Scholar
• TASKAR VS, SHARMA RR, GOSWAMI R, JOHN PJ, MAHASHUR AA: Effect of bromhexeine on sputum amoxycillin levels in lower respiratory infections. Respir Med. (1992) 86:157–160.
   PubMed Web of Science ®Google Scholar
• BERGOGNE-BEREZIN E, BERTHELOT G, KAFE HP, DOURNOVO P: Influence of a fluidifying agent (bromhexine) on the penetration of antibiotics into respiratory secretions. Int. J. Chu. Pharmacol. Res. (1985) 5:341–344.
   PubMed Web of Science ®Google Scholar
• ZIMENT I: History of the treatment of chronic bronchitis. Respiration (1991) 58 (Suppl. 1):37–42.
   Google Scholar
• PAVIA D, AGNEW JE, GLASSMAN JM et al.: Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients. Eur. j Respir: Dis. (1985) 67:177–184.
   PubMedGoogle Scholar
• PETTY TL: The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest (1990) 97:75–83.
   Google Scholar
• RUBIN BK, RAMIREZ 0, OHAR JA: Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest (1996) 109:348–352.
   PubMed Web of Science ®Google Scholar
• GOMOLIN IH: More on the toxicity of iodinated glycerol. jAm. Ceriatr. Soc. (1989) 37:486–487.
   PubMed Web of Science ®Google Scholar
• DRINKA PJ, NOLTEN WE: Effects of iodinated glycerol on thyroid function studies in elderly nursing home residents. Am. Ceriam Soc. (1988) 36:911–913.
   Web of Science ®Google Scholar
• GOMOLIN IH: Iodinated glycerol-induced hypothyroidism. Drug Intell. Chu. Pharm. (1987) 21:726–727.
   PubMed Web of Science ®Google Scholar
• HUSEBY JS, BENNETT SW, HAGENSEE ME: Hyperthyroidism induced by iodinated glycerol. Am. Rev. Respir Dis. (1991) 144:1403.
   PubMed Web of Science ®Google Scholar
• BLOCK SH: Goiter complicating therapy with iodinated glycerol (Organidin). I Pediam (1973) 83:84–86.
   Web of Science ®Google Scholar
• GEURIAN K, BRANAM C: Iodine poisoning secondary to long-term iodinated glycerol therapy. Arch. Intern. Med. (1994) 154:1153–1156.
   PubMed Web of Science ®Google Scholar
• DE ROSA G, DONATI C, HODEL CM: Domiodol. In: Drugs in Bronchial Mucology. Braga PC, Allegro L (Eds.) Raven Press, New York, USA (1989).
   Google Scholar
• FERRARI S, DONATI C, LEGNANI W: Studio clinico controllato dell'attivata terapeutica del domiodolo. Riv. Patol. Chu. (1981) 36:139–154.
   Google Scholar
• SHAK S, CAPON DJ, HELLMISS R, MARSTERS SA, BAKER CL: Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. USA (1990) 87:9188–9192.
   PubMed Web of Science ®Google Scholar
• SHAK S: Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest (1995) 107:65S–70S.
   Google Scholar
• SHAH PL, SCOTT SE KNIGHT RA, MARRIOTT C, RANASINHA C, HODSON ME: In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax (1996) 51:119–125.
   PubMed Web of Science ®Google Scholar
• WILLS PJ, WODEHOUSE T, CORKERY K, MALLON K, WILSON R, COLE PJ: Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am. 1. Respir: Grit. Care Med. (1996) 154:413–417.
   Google Scholar
• PUCHELLE E, ZAHM JM, DE BENTZMANN S et al.: Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur. Respir 1 (1996) 9:765–769.
   Google Scholar
• THOMPSON AB, FUCHS H, CORKERY K, PUN E, FICK RB: Phase II trial of recombinant human DNase for the therapy of chronic bronchitis. Am. Rev Respir. Dis. (1993) 147 (Suppl.):A318 (Abstract).
   Google Scholar
• FICK RB, ANZEUTO A, MAHUTTE KMott-CSG: Recombinant DNase mortality reduction in acute exacerbations of chronic bronchitis. Chu. Res. (1994) 42:294A (Abstract).
   Google Scholar
• BONE RC, FUCHS H, FOX NL et al.: The chronic obstructive pulmonary disease mortality endpoint trial. Chest (1995) 108 (Suppl.):R (Abstract).
   Google Scholar
• FIEL S: Chronic obstructive pulmonary disease. Mortality and reduction. Drugs (1996) 52 (Suppl. 2):55–60.
   Google Scholar
• HUDSON TJ: Dornase in treatment of chronic bronchitis. Ann. Pharmacother. (1996) 30:674–675.
   PubMed Web of Science ®Google Scholar
• VASCONCELLOS CA, ALLEN PG, WOHL ME, DRAZEN JM, JANMEY PA, STOSSEL TP: Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science (1994) 263:969–971.
   PubMed Web of Science ®Google Scholar
• FULORIA M, RUBIN BK: Evaluating the efficacy of mucoactive aerosol therapy. Respir Care (2000) 45:868–873.
   PubMedGoogle Scholar
• POOLE PJ, BLACK PN: Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane. Database. Syst. Rev CD0012872000.
   Google Scholar
• TASK GROUP ON MUCOACTIVE DRUGS: Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task group on mucoactive drugs. Chest (1994) 106:1532–1537.
   Google Scholar
• •Recommendations for improvements to clinical trials of mucolytic drugs in COPD.
   Google Scholar
• DEL DONNO M, OLIVIERI D: Mucoactive drugs in the management of chronic obstructive pulmonary disease. Monaldi Arch. Chest Dis. (1998) 53:714–719.
   PubMedGoogle Scholar
• GRANDJEAN EM, BERTHET PH, RUFFMANN R, LEUENBERGER P: Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol. Res. (2000) 42:39–50.
   PubMed Web of Science ®Google Scholar
• •Analysis of the cost-effectiveness of mucolytic treatment with N-acetylcycsteine showing effectiveness in treatment of severely ifi patients who are prone to exacerbations.
   Google Scholar